In ₹ Crore except Per Share Latest Annual | NECLIFE FY26 | AAREYDRUGS FY26 | NATCAPSUQ FY26 | MEDICAMEQ FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | — | 68.34× | — | ◆ 41.83× | 55.08× | |
| P/B | ◆ 0.40× | 1.80× | — | 1.49× | 1.64× -76% | |
| EV/EBITDA | ◆ -3.59× | 44.46× | — | 21.75× | 33.11× -111% | |
| Market Cap | ₹231 Cr | ₹270 Cr | — | ₹410 Cr | ₹340 Cr -32% | |
| Growth | ||||||
| Revenue CAGR 3Y | -81.73% | ◆ 96.26% | — | 11.97% | 54.12% -251% | |
| Revenue CAGR 5Y | -64.04% | — | — | — | — | |
| Net Income CAGR 3Y | — | ◆ 100.20% | — | -12.71% | 43.75% | |
| Revenue YoY (latest Q) | -99.99% | -56.34% | 7.76% | ◆ 11.27% | 7.76% -1389% | |
| Net Income YoY (latest Q) | ◆ 75.65% | -25.36% | -2.93% | 15.35% | -2.93% +2682% | |
| Profitability | ||||||
| EBITDA Margin | — | 1.52% | -0.83% | ◆ 9.90% | 1.52% | |
| Net Income Margin | -3152.45% | 0.84% | -13.17% | ◆ 4.95% | 0.84% -375392% | |
| Return on Common Equity | -50.30% | 2.64% | -7.27% | ◆ 3.50% | 2.64% -2005% | |
| Return on Capital Employed | -10.25% | 2.84% | -6.42% | ◆ 4.35% | 2.84% -461% | |
| Return on Assets | -47.12% | 1.33% | -5.81% | ◆ 2.63% | 1.33% -3643% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.00× | 0.33× | 0.49× | 0.17× | 0.33× -100% | |
| Interest Coverage | -1.69× | 0.86× | -1.71× | ◆ 3.54× | 0.86× -297% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹0 Cr | ₹472 Cr | ₹187 Cr | ₹198 Cr | ₹198 Cr -100% | |
| Net Income | −₹293 Cr | ₹4 Cr | −₹24.7 Cr | ₹9.8 Cr | ₹4 Cr -7482% | |
| Total Assets | ₹622 Cr | ₹297 Cr | ₹424 Cr | ₹372 Cr | ₹372 Cr +67% | |
| EPS | ₹-13.4 | ₹1.39 | ₹-23.84 | ₹7.22 | ₹1.39 -1064% | |
| Book Value per Share | ₹29.97 | ₹52.86 | ₹225.99 | ₹203.17 | ₹203.17 -85% | |